Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: A 1-year study

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 3, 2010, Pages 299-305

  Li, Mei ^a   Xing, Xiao Ping ^a   Zhang, Zhen Lin ^c   Liu, Jian Li ^c   Zhang, Zhong Lan ^b   Liu, Dong Gang ^d   Xia, Wei Bo ^a   Meng, Xun Wu ^a  

^a BEIJING HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Alendronate; Bone mineral density; Bone turnover marker; Ibandronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCICHEW D; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BONE DENSITY; BONE PAIN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; JAW OSTEONECROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLOOD; BODY HEIGHT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHINA; COMPARATIVE STUDY; DRUG EFFECT; FEMUR; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR VERTEBRA; MIDDLE AGED; MUSCLE DISEASE; PAIN; TIME;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BODY HEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CHINA; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FEMUR; FEMUR NECK; HUMANS; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MIDDLE AGED; MUSCULAR DISEASES; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN; PEPTIDES; TIME FACTORS;

EID: 77956017888     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0126-y     Document Type: Article

References (23)

1. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
2. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determination of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236-242
3. Penning-van Beest FJ, Erkens JA, Olsen M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511-517
4. Gallagher A, Rietbrock S, Olsen M, van Staa T (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569-1575
5. Croom KF, Scott LJ (2006) Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66:1593-1603
6. Zaidi M (2005) Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone (NY) 37:433-440
7. Chesnut IC, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
8. Sambrook P (2007) Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. Clin Interv Aging 2:65-72
9. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310
10. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245
11. Rizzoli R, Reid DM (2007) Ibandronate: an IV injection for the treatment for postmenopausal osteoporosis. Bone (NY) 41:S24-S28
12. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838-1846
13. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P (2003) Ibandronate Intravenous Study Group. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62:969-975
14. Kudlacek S, Schneider B, Peterlik M, Leb G, Klaushofer K, Weber K, Woloszczuk W, Willvonseder R (2003) Normative data of bone mineral density in an unselected adult Austrian population. Eur J Clin Invest 33:332-339
15. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR (1995) Comparison of methods for defining prevalent vertebral deformities: the Study of osteoporotic fractures. J Bone Miner Res 10:890-902
16. Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogencontaining bisphosphonates. J Dent Res 86:1022-1033
17. Müller R, Recker RR (2007) Bisphosphonate action on bone structure and strength: preclinical and clinical evidence for ibandronate. Bone (NY) 41:S16-S23
18. Civitelli R, Napoli N, Armamento-Villareal R (2007) Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 5:8-13
19. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
20. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315-1322 (Pubitemid 41033514)
21. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG (2008) Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, openlabel, prospective evaluation. Clin Ther 30:605-621
22. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone (NY) 34:881-889
23. Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD (2006) Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 29:1133-1152